Author/Editor		Zgonc, Vid; Čebular, Boštjan
Title		Sodobno medikamentno zdravljenje epilepsije pri odraslih
Translated title		Modern medicamentous treatment of epilepsy in adults
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 75, št. 6-7
Publication year		2006
Volume		str. 379-88
Language		slo
Abstract		Background Several »newer« antiepileptic drugs (AEDs), i. e. vigabatrin, lamotrigine, gabapentin, topiramate, tiagabine, oxcarbazepine, levetiracetam, pregabalin and zonisamide have been introduced into clinicalpractice within the lastdecade. Most of these new drugs are atleast as effective as the »older"AEDs (phenobarbital, phenytoin, valproic acid, carbamazepine) and in general, they seem to be better tolerated then the older drugs and have less side effects. The development of pharmaceutical industry has brought several new AEDs to clinical practice which increased a probability of therapeutic success, but also made treatment more complex. It is expected from the physician that she will know indications and contraindications for at least IS AEDs, their optimal titration, dosage, possible side effects and wide spectrum of interactions with other drugs. At this point advertisements of drug companies try to convince us aggressively about success of their own products. Conclusion This review article focuses on modern medicamentous treatment of adults with epilepsy, main characteristics of newer AEDs, conditionsm availability and statistics of their usage in Slovenia.
Summary		Izhodišča V zadnjih 10 letih so se v klinični praksi uveljavila številna »novejša« protiepileptična zdravila (PEZ), kot so vigabatrin, lamotrigin, gabapentin, topiramat, tiagabin, okskarbazepin, levetiracetam, pregabalin in zonisamid. Večinoma so vsaj tako učinkovita kot »starejša« PEZ (fenobarbital, fenitoin, valproat, karbamazepin), le da jih bolniki veliko bolje prenašajo in imajo manj neželenih učinkov. Razvoj farmacevtske industrije je prinesel številna novejša PEZ, ki so povečala verjetnost terapevtskega uspeha, a tudi povečala zapletenost zdravljenja. Od zdravnika se pričakuje, da bo poznal indikacije in kontraindikacijeza vsaj 15 PEZ, njihovo optimalno titracijo, odmerjanje, možne neželene učinke in širok spekter interakcij z drugimi zdravili. Pri tem nas marketinški oglasi proizvajalcev zdravil vse siloviteje prepričujejo o uspešnosti prav njihovih izdelkov. Zaključki Nastal je pregledni članek, ki govori o sodobnem medikamentnem zdravljenju odraslih z epilepsijo, stanju in dostopnosti novejših PEZ v Sloveniji, njihovih glavnih značilnostih in statistiki uporabe v Sloveniji.
Descriptors		EPILEPSY ANTICONVULSANTS